Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2025-10-22 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司关于向特定对象发行股票部分限售股份解除限售上市流通的提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding the lifting of restrictions on certain restricted shares issued to specific investors by Jinling Pharmaceutical Co., Ltd. It includes information about the number of shares becoming freely tradable, the dates of lifting restrictions, shareholder commitments, shareholding structure changes, and the sponsor's verification opinion. The document references regulatory approvals from the China Securities Regulatory Commission and Shenzhen Stock Exchange rules. It is not a financial report, earnings release, or management discussion but a formal disclosure about share capital changes related to restricted shares becoming tradable. This fits the definition of a Share Issue/Capital Change (SHA) filing, as it concerns changes in share capital structure and share circulation status.
2025-10-22 Chinese
金陵药业股份有限公司关于限制性股票回购注销完成的公告
Transaction in Own Shares Classification · 95% confidence The document is an official announcement from Jinling Pharmaceutical Co., Ltd. regarding the completion of the repurchase and cancellation of restricted shares under the 2021 restricted stock incentive plan. It details the number of shares repurchased and cancelled, the reasons for repurchase, adjustments to repurchase prices, funding sources, verification by an accounting firm, and the impact on the company's share capital structure. The document is a formal disclosure about a share repurchase and cancellation event, not a financial report, earnings release, or management discussion. It fits the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares. The document length is over 5,000 characters and contains detailed information about the transaction, confirming it is not merely an announcement of a report publication or a regulatory filing. Therefore, the correct classification is POS with high confidence.
2025-10-15 Chinese
金陵药业股份有限公司关于分公司收到药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Jinling Pharmaceutical Co., Ltd. regarding the receipt of a drug clinical trial approval notice from the National Medical Products Administration. It details the approval of a Phase III clinical trial for a drug named Olagolip. The document includes product information, regulatory approval details, and a risk warning to investors. It does not contain financial statements, management discussion, or detailed financial data. It is an announcement about regulatory approval related to drug development, not a financial report or earnings release. The document length is short (933 characters) and it is clearly an announcement of a regulatory event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-09-03 Chinese
金陵药业股份有限公司监事会关于第九届监事会第十九次会议相关事项的审核意见
Audit Report / Information Classification · 95% confidence The document is a supervisory board's audit opinion on the company's 2025 semi-annual report and related financial adjustments. It references the half-year report and compliance with laws and regulations, indicating it is an audit or review of financial data rather than the full report itself. The document length is short (789 characters) and it contains supervisory opinions and certifications rather than full financial statements or detailed financial analysis. Therefore, it fits best as an Audit Report / Information (AR) rather than the full Interim / Quarterly Report (IR). H1 2025
2025-08-27 Chinese
金陵药业股份有限公司2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2025 年半年度报告全文" which translates to the "2025 Semi-Annual Report Full Text" for Jinling Pharmaceutical Company Limited. It contains detailed financial data, management discussion and analysis, business overview, financial indicators, and other substantive financial and operational information for the half-year period ending June 30, 2025. The document length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The content includes financial statements, management commentary, business segment analysis, and risk disclosures, all typical of an Interim / Quarterly Report. There is no indication that this is an announcement of a report or a certification letter. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-27 Chinese
金陵药业股份有限公司第九届监事会第十九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Jinling Pharmaceutical Co., Ltd. It details the convening and decisions of the 19th meeting of the 9th Supervisory Board, including approvals of financial data adjustments, a special report on the use of raised funds, and the 2025 semi-annual report and its summary. However, the document itself does not contain the full semi-annual report or detailed financial statements; instead, it references that the full reports and related opinions are published elsewhere (on August 28, 2025, in designated newspapers and websites). The document is short (1098 characters) and serves as an official announcement of meeting resolutions and references to other reports rather than the reports themselves. According to the "Menu vs Meal" rule, this is an announcement of resolutions and references to reports, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories and is not the full semi-annual report (IR).
2025-08-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.